Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etiologics ltd.

David A Campbell1, Mary F Fitzgerald

  • 1Etiologics Ltd, Medical Research Council, Harwell, Oxfordshire, OX11 0RD, UK. david.campbell@etiologics.com

Pharmacogenomics
|April 30, 2003
PubMed
Summary
This summary is machine-generated.

Etiologics pioneers novel therapies for respiratory and metabolic diseases using ethylnitrosourea (ENU) technology and advanced preclinical models. The company aims to address critical unmet medical needs through comprehensive drug discovery expertise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA).

Respiratory research·2026
Same author

Impact of Preoperative Education on Clinical Outcomes Following Major Head & Neck Surgery: A Systematic Review.

OTO open·2025
Same author

Initial Direct Laryngoscopy Versus TORS Alone for Unknown Primary HPV+ Oropharyngeal Squamous Cell Carcinoma.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2025
Same author

Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment.

Nature communications·2025
Same author

Unveiling Prescribing Patterns: A Systematic Review of Chronic Opioid Prescriptions After Head and Neck Cancer Surgeries.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2025
Same author

Pulmonary-delivered Anticalin Jagged-1 antagonists reduce experimental airway mucus hyperproduction and obstruction.

American journal of physiology. Lung cellular and molecular physiology·2024
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
Same journal

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
See all related articles

Area of Science:

  • Biotechnology
  • Drug Discovery
  • Genetics

Background:

  • High unmet medical needs exist in respiratory and metabolic diseases.
  • Traditional drug discovery methods face challenges in identifying novel therapies.

Purpose of the Study:

  • To introduce Etiologics, a drug discovery company with a unique, integrated approach.
  • To highlight the company's focus on developing novel therapies for respiratory and metabolic diseases.
  • To showcase Etiologics' capabilities and partnership opportunities.

Main Methods:

  • Utilizing ethylnitrosourea (ENU) technology for genetic mutation induction.
  • Employing diverse animal models of disease and in vitro cell function models.
  • Leveraging comprehensive drug discovery expertise across the entire pipeline.

Related Experiment Videos

Main Results:

  • Etiologics possesses a balanced portfolio encompassing ENU technology, disease models, and drug discovery expertise.
  • The company is positioned to identify and develop effective therapies for challenging diseases.
  • Partners can access ENU technology and preclinical models for target identification and validation.

Conclusions:

  • Etiologics offers a robust platform for advancing drug discovery in respiratory and metabolic diseases.
  • The company's integrated approach and specialized technologies provide significant value to partners.
  • Etiologics is poised to make impactful contributions to treating diseases with high unmet needs.